Background
Phase III, double-blind, placebo-controlled RCT (ROBUST). 570 patients with previously untreated ABC-type DLBCL (cell-of-origin assigned by Lymph2Cx gene expression profiling from FFPE tissue — more rigorous than IHC). Lenalidomide, an immunomodulatory agent affecting IRF4-dependent NF-κB signaling, was hypothesized to target the ABC subtype's dependence on this pathway.
Interventions and follow up
Arm A: R-CHOP + lenalidomide (R²-CHOP) — lenalidomide 15 mg orally days 1–14 of each 21-day cycle × 6 cycles (n=285)
Arm B: R-CHOP + placebo × 6 cycles (n=285)
Primary endpoint: PFS (ITT)
Median follow up: 26.5 months
Arm B: R-CHOP + placebo × 6 cycles (n=285)
Primary endpoint: PFS (ITT)
Median follow up: 26.5 months
Results
2-yr PFS (R²-CHOP vs. R-CHOP): 65.7% vs. 64.4%, HR 0.85 (95% CI 0.63–1.14), P=.29 — negative
CR rate: 68.1% vs. 69.5% — not significantly different
2-yr OS: 78.8% vs. 79.0% — no difference
CR rate: 68.1% vs. 69.5% — not significantly different
2-yr OS: 78.8% vs. 79.0% — no difference
Adverse events
Grade ≥3 AEs: 80% (R²-CHOP) vs. 72% (R-CHOP)
Hematologic/cutaneous (grade ≥3): neutropenia 57% vs. 38%; rash 3% vs. <1%; DVT/PE 3% vs. 1%
Other: R-CHOP dose reductions more frequent with lenalidomide; treatment-related mortality comparable
Hematologic/cutaneous (grade ≥3): neutropenia 57% vs. 38%; rash 3% vs. <1%; DVT/PE 3% vs. 1%
Other: R-CHOP dose reductions more frequent with lenalidomide; treatment-related mortality comparable
Conclusions
R²-CHOP did not improve PFS or OS in ABC-type DLBCL (HR 0.85, P=.29). Despite the more rigorous Lymph2Cx RNA-based COO assignment, lenalidomide added no efficacy and increased toxicity compared to R-CHOP alone.
Key Limitations
Despite RNA-based COO profiling (more accurate than IHC), the ABC classification did not identify a lenalidomide-sensitive subgroup, challenging the hypothesis that ABC DLBCL is uniformly lenalidomide-sensitive. The 15 mg dose may be insufficient for full immunomodulatory activity; higher doses are toxic here. Lenalidomide's mechanism in DLBCL may require specific molecular contexts (e.g., CRBN expression) absent in many ABC cases. Lenalidomide is approved in R/R DLBCL (L-MIND combination) but not frontline.
Clinical Context
ROBUST and PHOENIX are the two major negative trials targeting the ABC/non-GCB subtype with targeted agents added to R-CHOP. Neither lenalidomide (ROBUST) nor ibrutinib (PHOENIX) improved outcomes despite rational hypotheses and COO-selected populations, highlighting the complex, redundant DLBCL signaling landscape. POLARIX (Pola-R-CHP) succeeded with an unselected approach targeting CD79b via ADC, suggesting antigen-targeting rather than downstream pathway inhibition is the more effective frontline strategy.
References